Free Trial
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

OptimizeRx logo
$4.87 +0.38 (+8.46%)
(As of 11/22/2024 ET)

About OptimizeRx Stock (NASDAQ:OPRX)

Key Stats

Today's Range
$4.47
$5.02
50-Day Range
$3.83
$8.16
52-Week Range
$3.78
$16.65
Volume
758,036 shs
Average Volume
351,982 shs
Market Capitalization
$89.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.42
Consensus Rating
Moderate Buy

Company Overview

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

OptimizeRx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

OPRX MarketRank™: 

OptimizeRx scored higher than 68% of companies evaluated by MarketBeat, and ranked 286th out of 647 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OptimizeRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about OptimizeRx's stock forecast and price target.
  • Earnings Growth

    Earnings for OptimizeRx are expected to grow in the coming year, from ($0.35) to ($0.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OptimizeRx is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OptimizeRx is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OptimizeRx has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.02% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    OptimizeRx does not currently pay a dividend.

  • Dividend Growth

    OptimizeRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.02% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in OptimizeRx has recently increased by 4.80%, indicating that investor sentiment is decreasing.
  • News Sentiment

    OptimizeRx has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OptimizeRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of OptimizeRx is held by insiders.

  • Percentage Held by Institutions

    76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OptimizeRx's insider trading history.
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) PT at $11.58
OptimizeRx to Participate in Upcoming Investor Conferences
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
OptimizeRx price target lowered to $8 from $13 at Stifel
OptimizeRx price target lowered to $8 from $16 at JMP Securities
OptimizeRx (OPRX) Gets a Buy from Stifel Nicolaus
OptimizeRx Reports Strong Revenue Growth in Q3 2024
See More Headlines

OPRX Stock Analysis - Frequently Asked Questions

OptimizeRx's stock was trading at $14.31 at the start of the year. Since then, OPRX stock has decreased by 66.0% and is now trading at $4.87.
View the best growth stocks for 2024 here
.

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, May, 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.16. The company had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. OptimizeRx had a negative trailing twelve-month return on equity of 4.92% and a negative net margin of 27.41%.

OptimizeRx's top institutional shareholders include Rice Hall James & Associates LLC (3.36%), Geode Capital Management LLC (2.16%), Essex Investment Management Co. LLC (1.32%) and Bullseye Asset Management LLC (1.17%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh, Ellen O'connor Vos and Miriam J Paramore.
View institutional ownership trends
.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2024
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
Business Services
Current Symbol
NASDAQ:OPRX
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.42
High Stock Price Target
$18.50
Low Stock Price Target
$5.00
Potential Upside/Downside
+113.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-17,570,000.00
Pretax Margin
-37.84%

Debt

Sales & Book Value

Annual Sales
$88.18 million
Book Value
$6.21 per share

Miscellaneous

Free Float
17,297,000
Market Cap
$89.71 million
Optionable
Optionable
Beta
1.32
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:OPRX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners